Monopar Therapeutics Inc. (MNPR)
Monopar Therapeutics Statistics
Share Statistics
Monopar Therapeutics has 6.11M shares outstanding. The number of shares has increased by -65.1% in one year.
| Shares Outstanding | 6.11M |
| Shares Change (YoY) | -65.1% |
| Shares Change (QoQ) | 0.43% |
| Owned by Institutions (%) | 2.62% |
| Shares Floating | 3.96M |
| Failed to Deliver (FTD) Shares | 638 |
| FTD / Avg. Volume | 1.36% |
Short Selling Information
The latest short interest is 51.82K, so 0.85% of the outstanding shares have been sold short.
| Short Interest | 51.82K |
| Short % of Shares Out | 0.85% |
| Short % of Float | 1.69% |
| Short Ratio (days to cover) | 1.62 |
Valuation Ratios
The PE ratio is -0.05 and the forward PE ratio is -18.36. Monopar Therapeutics's PEG ratio is 0.
| PE Ratio | -0.05 |
| Forward PE | -18.36 |
| PS Ratio | 0 |
| Forward PS | 3 |
| PB Ratio | 0.02 |
| P/FCF Ratio | -0.13 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Monopar Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.01, with a Debt / Equity ratio of 0.
| Current Ratio | 0.01 |
| Quick Ratio | 0.01 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.11B |
| Employee Count | 14 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 1043.07% in the last 52 weeks. The beta is 1.02, so Monopar Therapeutics's price volatility has been higher than the market average.
| Beta | 1.02 |
| 52-Week Price Change | 1043.07% |
| 50-Day Moving Average | 36.84 |
| 200-Day Moving Average | 19.47 |
| Relative Strength Index (RSI) | 57.1 |
| Average Volume (20 Days) | 46.94K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -16.16B |
| Net Income | -15.59B |
| EBITDA | -16.16B |
| EBIT | n/a |
| Earnings Per Share (EPS) | -411.23 |
Balance Sheet
The company has 45.82M in cash and 0 in debt, giving a net cash position of 45.82M.
| Cash & Cash Equivalents | 45.82M |
| Total Debt | 0 |
| Net Cash | 45.82M |
| Retained Earnings | -75.79B |
| Total Assets | 60.29M |
| Working Capital | 55.04M |
Cash Flow
In the last 12 months, operating cash flow was -6.4B and capital expenditures 0, giving a free cash flow of -6.4B.
| Operating Cash Flow | -6.4B |
| Capital Expenditures | 0 |
| Free Cash Flow | -6.4B |
| FCF Per Share | -168.97 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MNPR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for MNPR is $50, which is 29% higher than the current price. The consensus rating is "Buy".
| Price Target | $50 |
| Price Target Difference | 29% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Stock Splits
The last stock split was on Aug 13, 2024. It was a backward split with a ratio of 1:5.
| Last Split Date | Aug 13, 2024 |
| Split Type | backward |
| Split Ratio | 1:5 |
Scores
| Altman Z-Score | 22.59 |
| Piotroski F-Score | 2 |